L treatment approval for Yescarta is a great achievement. It gives the patients with this deadly disease a great hope. Assuming Yescarta can only treat 10% of FL patients, it means 500M revenue to GILD. It has a tremendous opportunities if it can move up the line of treatment down the FOSTER CITY, Calif.-
もう一つも良い結果
-(BUSINESS WIRE)--Mar. 6, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).
約500億の売上
L treatment approval for Yescarta is a great achievement. It gives the patients with this deadly disease a great hope. Assuming Yescarta can only treat 10% of FL patients, it means 500M revenue to GILD. It has a tremendous opportunities if it can move up the line of treatment down the FOSTER CITY, Calif.-
もう一つも良い結果
-(BUSINESS WIRE)--Mar. 6, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).